CSL Behring GmbH
PolandAll drugs from this manufacturer
-
The medicine is used to replenish and maintain circulating blood volume. It is typically used in situations requiring intensive therapy when blood volume has dropped drastically, for example, after a severe injury leading to blood loss or after extensive burns.
Dosage form: solution for infusion
Active substance Dosage total protein less or equal to 96% human albumin 200 g ATC: B05AA01
-
The medicine is used to supplement and maintain circulating blood volume. It is usually administered in intensive care situations when blood volume has critically decreased, for example, after severe injury leading to blood loss or after extensive burns.
Dosage form: solution for infusion
Active substance Dosage total protein 50 g ATC: B05AA01
-
Beriate is used for the prophylaxis and treatment of bleeding caused by a deficiency of coagulation factor VIII (hemophilia type A) and in the treatment of acquired deficiency of this factor. The drug helps to temporarily improve blood clotting mechanisms.
Dosage form: solution for injection / infusion, powder and solvent for preparation of
ATC: B02BD02
-
The medicine is used to treat and prevent the occurrence of swelling (edema) during procedures in individuals suffering from hereditary angioedema type I and II.
Dosage form: solution for injection, powder and solvent for preparation of
Active substance Dosage human c1 esterase inhibitor 450-625 IU/ml ATC: B02AB03
-
The medicinal product is used for the prevention of recurrent attacks of hereditary angioedema (HAE) in adolescents and adults.
Dosage form: solution for injection, powder and solvent for preparation of
Active substance Dosage human c1 esterase inhibitor 2000 j.m. ATC: B06AC01
-
The medicine is used for protection against recurrent attacks of hereditary angioedema (HAE) in adolescents and adults.
Dosage form: solution for injection, powder and solvent for preparation of
Active substance Dosage human c1 esterase inhibitor 3000 j.m. ATC: B06AC01
-
The medicine is used to treat and prevent the occurrence of swelling (edema) during procedures in people suffering from hereditary angioedema type I and II (HAE).
Dosage form: solution for injection or infusion, powder and solvent for preparation of
Active substance Dosage human c1 esterase inhibitor 40.0 - 62.5 J/ml ATC: B06AC01
-
The medicinal product is used for the treatment and prevention of bleeding caused by congenital or acquired deficiency of vitamin K-dependent blood clotting factors. It is also used during surgical procedures.
Dosage form: solution for injection, powder and solvent for preparation of
Active substance Dosage human prothrombin complex 1000 j.m. ATC: B02BD01
-
The medicinal product is used for the treatment and prevention of bleeding caused by congenital or acquired deficiency of vitamin K-dependent blood clotting factors (II, VII, IX, and X), especially when another appropriate preparation is unavailable.
Dosage form: solution for injection, powder and solvent for preparation of
Active substance Dosage human coagulation factor ii 200-480 j.m. human coagulation factor vii 100-250 j.m. human coagulation factor ix 200-310 IU human coagulation factor x 220-600 j.m. c protein 150-450 j.m. s protein 130-260 j.m. ATC: B02BD01
-
The medicinal product is used for the treatment and prevention of bleeding caused by congenital or acquired deficiency of vitamin K-dependent blood coagulation factors (II, VII, IX, and X). It is also used to prevent bleeding during surgical procedures.
Dosage form: solution for injection, powder and solvent for preparation of
Active substance Dosage human coagulation factor x 440-1200 j.m. human coagulation factor vii 200-500 j.m. c protein 300-900 j.m. human coagulation factor ix 400-620 j.m. s protein 260-520 j.m. human coagulation factor ii 400-960 j.m. ATC: B02BD01
-
The medicinal product is used in adults, children, and adolescents for the prophylactic treatment of congenital factor XIII deficiency and for the treatment of bleeding during surgical procedures in patients with this deficiency.
Dosage form: powder and solvent for solution for injection and infusion
Active substance Dosage factor xiii 1250 j.m. (1000 - 1600 j.m.) ATC: B02BD07
-
The medicinal product is used in adults, children, and adolescents for the prophylactic treatment of congenital factor XIII deficiency and for the treatment of bleeding during surgical procedures in patients with this deficiency.
Dosage form: powder and solvent for solution for injection and infusion
Active substance Dosage factor xiii 250 IU (200 - 320 IU) ATC: B02BD07
-
The medicinal product is used for the prophylaxis and treatment of bleeding caused by a deficiency of von Willebrand factor (von Willebrand disease) or a deficiency of factor VIII (haemophilia A). It may also be used in the therapy of acquired factor VIII deficiency and in patients with antibodies against it.
Dosage form: solution for injection or infusion, powder and solvent for preparation of
Active substance Dosage human coagulation factor viii 1000 j.m. von willebrand factor human 2400 j.m. ATC: B02BD06
-
The medicinal product is used for the prophylaxis and treatment of bleeding in individuals with von Willebrand disease and in haemophilia A (factor VIII deficiency). It may also be used in the therapy of acquired factor VIII deficiency and in patients possessing antibodies against this factor.
Dosage form: solution for injection or infusion, powder and solvent for preparation of
Active substance Dosage human coagulation factor viii 250 j.m. von willebrand factor human 600 j.m. ATC: B02BD06
-
The medicinal product is used for the prophylaxis and treatment of bleeding caused by a deficiency of von Willebrand factor (von Willebrand disease) or a deficiency of factor VIII (haemophilia A). It may also be used in the treatment of acquired factor VIII deficiency and in patients with antibodies against it.
Dosage form: solution for injection or infusion, powder and solvent for preparation of
Active substance Dosage human coagulation factor viii 500 j.m. von willebrand factor human 1200 j.m. ATC: B02BD06
-
The medicine is used to replenish and maintain circulating blood volume. It is typically used in situations requiring intensive care, when blood volume has critically decreased, for example, after severe trauma leading to blood loss or after extensive burns.
Dosage form: solution for infusion
Active substance Dosage total protein 200 g/l ATC: B05AA01
-
The medicinal product is used in the treatment of congenital and acquired antithrombin III deficiency. It helps in the treatment of deep vein thrombosis and thromboembolic disease, often in combination with heparin.
Dosage form: powder and solvent for preparation of infusion solution
Active substance Dosage antithrombin iii up to 1 ml ATC: B01AB02
-
The medicine is used to prevent the formation of antibodies in individuals with Rh(D) negative blood group who have been exposed to Rh(D) positive blood. This primarily concerns pregnant women (in case of risk of contact with the baby's blood, e.g., after childbirth, miscarriage, or pregnancy complications) as well as adults and children who have accidentally received the wrong blood group during a transfusion.
Dosage form: solution for injection
Active substance Dosage human anti-d immunoglobulin 300 mcg (1500IU)/2 ml ATC: J06BB01
-
Riastap is used to treat bleeding in individuals with congenital fibrinogen deficiency, which causes an increased tendency to bleed.
Dosage form: powder for preparation of solution for injection or infusion
Active substance Dosage human fibrinogen 1 g ATC: B02BB01
-
It is used for dissolving and diluting other medicinal products that must be mixed with water before administration by injection or infusion (intravenous, intramuscular, or other tissues).
Dosage form: solution for preparation of parenteral drugs
Active substance Dosage water for injection No input provided ATC: V07AB